Inflammatory bowel disease: Jakinibs are the most recent therapeutic agents for managing chronic inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease, exhibiting better pharmacokinetic and lack of immunogenicity compared to other biological counterparts (TNF inhibitors) (Hernandez-Rocha and Vande Casteele, 2020). Here, TNF is linked to ulcerative colitis.